View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 16, 2020

Roivant starts gimsilumab dosing in Covid-19 trial

Roivant Sciences has dosed the first participant in the BREATHE clinical trial of monoclonal antibody gimsilumab to treat Covid-19 patients with lung injury or acute respiratory distress syndrome (ARDS).

Roivant Sciences has dosed the first participant in the BREATHE clinical trial of monoclonal antibody gimsilumab to treat Covid-19 patients with lung injury or acute respiratory distress syndrome (ARDS).

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

Dosing occurred at Temple University Hospital, Philadelphia, and will be immediately commenced at other sites.

Gimsilumab is a fully human monoclonal antibody that acts on granulocyte-macrophage colony-stimulating factor (GM-CSF).

Roivant evaluated the drug in various non-clinical studies and two clinical studies, including a four-week Phase I study in healthy volunteers.

Data revealed a favourable safety and tolerability profile.

The new adaptive, randomised, double-blind, placebo-controlled, multi-centre trial will assess the effect of the drug’s intravenous (IV) formulation on mortality in Covid-19 patients.

It is designed to recruit up to 270 patients with confirmed Covid-19 and clinical evidence of acute lung injury or ARDS. Participants will receive gimsilumab or placebo.

The primary endpoint is incidence of mortality by day 43, while key secondary endpoints include the incidence and duration of mechanical ventilation use, number of ICU days and inpatient hospitalisation days.

Harvard Medical School medicine professor Dr Mandeep Mehra said: “GM-CSF-targeted immunomodulation to address the aberrant host immune response in Covid-19 appears promising for reducing lung injury and death in this aggressive illness.

“The rapid initiation of this pivotal trial with gimsilumab is impressive given the pressing need for effective therapies that reduce the morbidity encountered with Covid-19.”

Some hospitalised Covid-19 patients have an overactive immune response that involves cytokine dysregulation and elevated inflammatory myeloid cells that cause lung injury, ARDS and death.

GM-CSF is thought to be involved in lung hyper-inflammation and upstream operation of other pro-inflammatory cytokines and chemokines.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena